On this page
What it is
A long-acting synthetic agonist at amylin receptors, developed by a major pharmaceutical company for weight management.
How it is proposed to work
Amylin receptor agonism affecting satiety and gastric emptying through a pathway distinct from GLP-1 — the same rationale behind cagrilintide, and the reason amylin analogues are being developed alongside incretins rather than instead of them.
Approved medical uses
None. Eloralintide has no approved human medical indication in the jurisdictions we track. Any use is outside an approved label.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Randomised controlled trial2025
Phase 2 trial in adults with obesity
Finding. Dose-dependent weight reduction reported. We state no percentages: our check found an internal contradiction between the reported adverse-event pattern and the described trial arms, meaning either the figures or their explanation is wrong.
Limitation. Phase 2. Effect sizes commonly shrink in phase 3, and no long-term or outcome data exists.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
No preclinical studies catalogued.
Potential safety concerns
- CautionPreliminary
Gastrointestinal effects are expected from the mechanism and were reported in trials. The dose-response pattern in the accessible reporting was not internally consistent, so we describe it no further.
- SeriousEstablished
An investigational compound in active development has no legitimate consumer supply. Anything sold is unverified material outside the trials that are still establishing its safety profile.
Known interactions and contraindication considerations
- Delayed gastric emptying can alter oral drug absorption. Combination effects with incretins need supervision.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Unapproved / investigational as of 11 Aug 2026 | Investigational, in active clinical development. No marketing authorisation. |
European Union EMA | Unapproved / investigational as of 11 Aug 2026 | No marketing authorisation. |
India CDSCO | Unapproved / investigational as of 11 Aug 2026 | Not approved for human use. A first-time synthetically manufactured peptide falls under the new-drug pathway. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
No community use documented for this compound yet. Absence here means our editorial team has not reviewed and verified a pattern — not that none exists.
Active clinical trials
No registered trials currently tracked for Eloralintide.
What remains unknown
The questions that would change our assessment if they were answered.
- Do the phase 2 results hold in phase 3?
- How does it compare with, and combine with, incretin therapy?
- What happens to lean mass?
References
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Dossier created. Phase 2 percentages excluded: the accessible reporting contained a contradiction between adverse-event rates and the stated trial-arm design.
Spotted something wrong? Tell us — we publish corrections.